In CRC, the JAK/STAT3 pathway can directly regulate tumor immune cells and upregulates the expression of oncogenic proteins, such as c-MYC, Cyclin D1, BCL2 or MCL1 to help drive tumor progression and chemoresistance [36]. Here, MYC is linked to neoplasm.